Direct-Acting Antiviral Prescribing for Hep C Peaked in 2015, Then Declined

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Amazon Big Spring Sale - Up to 40% off

Medically reviewed by Judith Stewart, BPharm. Last updated on March 27, 2026.

via HealthDay

FRIDAY, March 27, 2026 -- Direct-acting antiviral (DAA) prescribing for hepatitis C virus (HCV) infection peaked in 2015, then declined, according to a research letter published online March 25 in the Journal of the American Medical Association.

Sanjay Kishore, M.D., from the University of Virginia School of Medicine in Charlottesville, and colleagues measured changes in patient and prescriber characteristics for DAAs from 2013 to 2025 in a cross-sectional study.

The researchers found that from 2013 to 2025, an estimated 1.3 million courses of DAA were dispensed, with the highest annual volume in 2015, declining to 2025 (185,677 to 68,523 courses). Prior to the introduction of newer regimens in 2016, which can be used to treat all HCV genotypes, prescribing reached its maximum number of courses. In 2015, most prescriptions were accounted for by Medicare and commercial insurance (36.8 and 44.7 percent, respectively), while the largest share in 2025 was accounted for by Medicaid (48.7 percent). Specialist prescribing declined from a peak in 2015 to 2025 (66.1 percent of DAA courses to 28.3 percent). Over time, there was a shift in the age distribution of patients being prescribed DAAs, with adults aged older than 61 years accounting for 41.8 and 26.0 percent of patients in 2015 and 2025, respectively; individuals younger than 40 years increased from 5.4 to 28.9 percent.

"Hepatitis C is a curable disease, but current treatment levels are substantially below what's needed to achieve national elimination targets," Kishore said in a statement.

One author disclosed serving as an expert witness against pharmaceutical companies, and one disclosed ties to a health insurance company.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-28 01:51

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords